Pulmonx Corporation: CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema

The reported data suggest that patients with collateral ventilation may be able to undergo successful treatment with Zephyr Endobronchial Valves following closure of collateral air channels with the

Related Keywords

Italy ,Australia ,United States ,France ,French ,Australian ,Meghan Oreste ,Michela Bezzi ,Pulmonx Zephyr ,Brian Johnston ,Global Initiative For Chronic Obstructive Lung Disease ,Pulmonx Corporation Nasdaq ,Macquarie University Hospital ,Exchange Commission ,University Hospital ,European Respiratory Society ,Department Head ,Gilmartin Group ,Securities Exchange ,Pulmonx Corporation ,Company Quarterly Report On Form ,International Conference ,Zephyr Endobronchial Valves ,Respiratory Society ,Aeriseal System ,Bronchoscopic Lung Volume Reduction ,Zephyr Valves ,Target Lobe Volume Reduction ,Zephyr Valve ,Residual Volume ,Six Minute Walk Distance ,Director Interventional Pulmonology ,Glen French ,Chief Executive Officer ,Zephyr Endobronchial ,Endobronchial Valves ,Global Initiative ,Chronic Obstructive Lung Disease ,Assessment System ,Analysis Platform ,Securities Act ,Securities Exchange Act ,Quarterly Report ,Pulmonx ,Corporation ,Convert ,Linical ,Trial ,Data ,Resented ,Emonstrates ,Early ,Success ,Eriseal ,System ,Patients ,Dvanced ,Copd ,Emphysema ,